Eysuvis
| Eysuvis | |
|---|---|
| DOSAGE | 1 gtt up to QID for up to 14 days |
| GENERIC | Loteprednol etabonate 0.25% |
| SIZE | 8.3 mL |
| INDICATIONS | EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. |
| MECHANISM OF ACTION | Ester based corticosteroid |
| MICROBIOLOGY | Thought to prevent dry eye caused by ocular inflammation associated with keratoconjunctivitis sicca | Loteprednol etabonate is lipid soluble and can penetrate into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites, PJ-91 and PJ-90. |
| CONTRAINDICATIONS & WARNINGS | Contraindicated in patients with viral, bacterial, or fungal eye infections |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients have not been established. |
| PREGNANCY | Category C |
| NOTE | |